Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q2 2024 Earnings Presentation
9 slides from Crinetics Pharmaceuticals's earnings presentation, Aug 8, 2024
Slide 1: Second Quarter Conference Call
CRINETICS PHARMACEUTICALS SECOND QUARTER CONFERENCE CALL August 8, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements.
Slide 3: Building a Premier Endocrine-focused Pharmaceutical Company
Building a Premier Endocrine-focused Pharmaceutical Company Strategic Approach to Growing Long-term Value 3
Slide 4: 2Q2024 Highlights
2Q2024 Highlights Unprecedented atumelnant data for CAH and Cushing's disease shared at ENDO Paltusotine patient-reported outcomes data shared at ENDO Development candidates selected for hyperparathyroidism and ADPKD programs Progress on regulatory milestones and preparation for paltusotine launch 4
Slide 5: Development and Regulatory Update
Development and Regulatory Update On track for submission of NDA for paltusotine in acromegaly in 2H2024 Preparing to discuss paltusotine carcinoid syndrome Phase 3 plans with FDA Atumelnant CAH Phase 2 study fully enrolled with topline data expected in 2H2024 On track to share additional data from
Slide 6: Our Launch Strategy is to Establish a New Medical Standard of Care in the Treatment of Acromegaly
Our Launch Strategy is to Establish a New Medical Standard of Care in the Treatment of Acromegaly Partnering with Empowering Patients Ensuring Optimal Endocrinology to Ask for Optimal Access to Therapy Physician Community Care Empower and engage with patients to convey that better care is possible i
Slide 7: Acro/Truth Disease Education
Acro/Truth Disease Education AcromegalyTruth.com 7
Slide 8: Financial Highlights
Financial Highlights Three months ended June 30, (in millions) 2024 2023 Revenues $ 0.4 $ 1.0 R&D Expenses 58.3 40.6 G&A Expenses 24.8 13.3 Net Loss $(74.1) $(51.0) Cash and equivalents totaled $863.0 million as of June 30, 2024, sufficient to fund the company’s current operating plan into 2028. 8
Slide 9: Crinetics is Building the Premier Endocrine-focused Pharmaceutical Company
Crinetics is Building the Premier Endocrine-focused Pharmaceutical Company Sales-Funded Growth Atumelnant Launch** Cushing’s Commercial Transition Atumelnant Launch** 2026+ CAH NDA Submission & Commercial Paltusotine Launch* Readiness Carcinoid Syndrome 2025 Paltusotine Launch* Acromegaly 2024 Conti
Crinetics Pharmaceuticals — Q2 2024 Earnings Presentation on 6ix